Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NeoGenomics, Inc. (NGNM) -- Ignore unavailable to you. Want to Upgrade?

To: caly who wrote (4)	7/20/2006 8:25:42 AM
From: Max Fletcher	Read Replies (1) \| Respond to of 30

I listened to the Q2 conference call. Much of what was said was included in the Q2 Press Release, but there were a few comments that expanded on that writeup: - management believes the results demonstrate they can scale profitably. Revenues grew 32% while Net Income grew 52%. The infrastructure is in place for dramatically increased revenue without significantly increased SG&A expenses. - there's a very astute analysis in the AMI research report on the economics of testing and the number of tests per requisition/avg revenue per requisition and the operating leverage that can be achieved (the full report can be downloaded here: americanmicrocapinstitute.com ) - they are testing a new product with a handful of customers that they hope will help differentiate their services in the marketplace. Details to be released later if they decide to expand the program - sufficient cash for 12 months, unless any strategic initiatives are undertaken - some of the large customers they've been targeting have been 'woefully underserved' in the past by the large labs, opening up a large opportunity for NGNM